Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients
Language English Country England, Great Britain Media print
Document type Journal Article
Grant support
IBD-COMFORT Foundation
PubMed
35358307
PubMed Central
PMC8992348
DOI
10.1093/ecco-jcc/jjac048
PII: 6561818
Knihovny.cz E-resources
- Keywords
- COVID-19, inflammatory bowel disease, vaccination,
- MeSH
- COVID-19 * prevention & control MeSH
- Immunity, Humoral MeSH
- Inflammatory Bowel Diseases * drug therapy MeSH
- Immunoglobulin G MeSH
- Interferon-gamma MeSH
- Humans MeSH
- Antibodies, Viral MeSH
- SARS-CoV-2 MeSH
- Vaccination MeSH
- COVID-19 Vaccines MeSH
- Viral Vaccines * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Immunoglobulin G MeSH
- Interferon-gamma MeSH
- Antibodies, Viral MeSH
- COVID-19 Vaccines MeSH
- Viral Vaccines * MeSH
BACKGROUND AND AIMS: Knowledge on the immunogenicity of anti-SARS-CoV-2 vaccines in inflammatory bowel disease [IBD] patients is limited. Therefore, SARS-CoV-2-specific T-cell responses and antibodies were analysed in 60 IBD vaccine recipients and 30 controls. METHODS: SARS-CoV-2 IgG antibodies against the viral spike protein were measured at baseline and at 8 and 26 weeks after the second vaccine dose. SARS-CoV-2 IgG antibodies against the nucleocapsid antigens were measured at week 26. A SARS-CoV-2 interferon-gamma released assay [IGRA] was performed in all vaccinees at week 26. RESULTS: At weeks 0 and 8, no differences were found in anti-spike antibodies between cohorts. At week 26, the decrease in antibody levels was more significant in the IBD cohort compared to the healthy cohort, and anti-nucleocapsid antibodies were not detected in either group. At week 26, 16 of 90 [18%] vaccinated individuals had a negative IGRA test result, seven of 90 [8%] were borderline and 67 [74%] had a positive IGRA result; 22 of the 23 individuals with negative or borderline IGRA results belonged to the IBD cohort. However, the overall functional ability of T-lymphocytes to produce interferon-gamma after the unspecific mitogen stimulation was lower in IBD patients. In vaccinated individuals with low or borderline IGRA, treatment with tumour necrosis factor-alpha inhibitors was the most frequent. In individuals with a significant drop in anti-spike antibody levels, plasmatic interferon-gamma concentrations after the specific SARS-CoV-2 stimulation were also insufficient. CONCLUSIONS: Simple humoral and cellular post-vaccination monitoring is advisable in IBD patients so that repeated vaccine doses may be scheduled.
AGILAB Group s r o Prague Czech Republic
Department of Internal Medicine University Hospital and Medical Faculty Ostrava Czech Republic
Institute for Postgradual Medical Education PragueCzech Republic
Institute of Animal Physiology and Genetics Czech Academy of Sciences Libechov Czech Republic
Institute of Pharmacology 1st Faculty of Medicine Charles University Prague Czech Republic
References provided by Crossref.org
